Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas Academic Article uri icon

Overview

MeSH Major

  • Angiogenesis Inhibitors
  • Glioma
  • Neoplasm Recurrence, Local
  • Supratentorial Neoplasms
  • Thalidomide

abstract

  • Thalidomide is a generally well-tolerated drug that may have antitumor activity in a minority of patients with recurrent high-grade gliomas. Future studies will better define the usefulness of thalidomide in newly diagnosed patients with malignant gliomas and in combination with radiotherapy and chemotherapy. Additionally, studies will be needed to confirm the potential utility of changes in serum bFGF as a marker of antiangiogenic activity and/or glioma growth.

publication date

  • February 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10673511

Additional Document Info

start page

  • 708

end page

  • 15

volume

  • 18

number

  • 4